Trials / Completed
CompletedNCT00590694
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
Determining Optimal Treatment Algorithms for Macular Degeneration Pigment Epithelial Detachments Treated With Intraocular Lucentis
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Pacific Eye Associates · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Patients with neovascular Age-related macular degeneration (AMD) and the particular feature of pigment epithelial detachments (PEDs) were not studied in the Phase III trials for ranibizumab (Lucentis). The PrONTO study was the first ranibizumab study to enroll such patients but only treated with ranibizumab until fluid within the layers of the retina was absent, not until the entire PED was absent. This study hypothesizes that there may be a difference in benefit between patients treated until just the retinal edema is gone and those in which the retinal edema and PED are both gone.
Conditions
- Age-related Macular Degeneration
- Pigment Epithelial Detachment
- Neovascular Macular Degeneration
- Wet Macular Degeneration
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab | 0.5mg injection monthly according to protocol for one year |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2008-01-11
- Last updated
- 2012-04-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00590694. Inclusion in this directory is not an endorsement.